CG
CNCE

Cutler Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Cutler Group’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-300
Closed -$2K – 5484
2017
Q4 		$2K Buy
+300
New +$6.04K ﹤0.01% 4268
2017
Q2 		– Sell
-5,000
Closed -$22K – 7316
2017
Q1 		$22K Buy
+5,000
New +$60K ﹤0.01% 3249
2016
Q2 		– Sell
-4,700
Closed -$2K – 7490
2016
Q1 		$2K Hold
4,700
– – ﹤0.01% 5731
2015
Q4 		$8K Buy
+4,700
New +$102K ﹤0.01% 4451

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cutler Group's CNCE Position: Q2 2019 in Review

Cutler Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 200 shares — an estimated $2K sold.

Cutler Group first reported a position in CNCE in Q4 2015 and held it in 8 quarters. The position peaked at $45K in Q1 2017. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

  • Cutler Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Cutler Group sold 200 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
  • Cutler Group first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 8 quarters.
  • Cutler Group's Concert Pharmaceuticals, Inc. position peaked at $45K in Q1 2017.
  • 87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Cutler Group's 13F filing for Q2 2019, filed 9 Aug 2019.